pharmacy podcast network

It's the GameChangers' Birthday! This episode is a rapid review of a few subjects to celebrate the first year of GameChangers. From oral iron administration to the use of metronidazole with alcohol or serotonin syndrome, this episode has all the ingredients for a celebration!GameChangers' host, Geoff Wall, just released new music! Check out his latest EP here: https://open.spotify.com/artist/0J26ngHZz2cf6mQR3UiEHW?827= or wherever you listen to music!Reference: Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533. doi: 10.1016/S2352-3026(17)30182-5. Epub 2017 Oct 9. PMID: 29032957.Kaundal R, Bhatia P, Jain A, et al. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol. 2020 Jan;99(1):57-63. doi: 10.1007/s00277-019-03871-z. Epub 2019 Dec 6. PMID: 31811360.Visapää JP, Tillonen JS, Kaihovaara PS, et al. Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother. 2002 Jun;36(6):971-4. doi: 10.1345/aph.1A066. PMID: 12022894.Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurol. 2018 May 1;75(5):566-572. doi: 10.1001/jamaneurol.2017.5144. PMID: 29482205; PMCID: PMC5885255.CPE details for GameChangers Podcast April 2021Learning Objective: Discuss the evidence-based dosing of oral iron supplementation.0107-0000-21-158-H01-P0.2 CEU/2 Hrs (Knowledge)Initial Release Date: 04/06/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

More and more vaccines are getting authorization in the United States to prevent COVID-19. However, sometimes a vaccine trial is not always effective. But even failure can provide new insights. Learn about the Janssen COVID-19 vaccine and what happened with the recent Hepatitis C vaccine candidate.This podcast was recorded prior to the joint CDC and FDA statement on the Johnson & Johnson/Janssen COVID-19 vaccine on April 13th. On April 13th, 2021, the CDC and FDA issued a joint statement recommending a pause on the use of the Johnson & Johnson/Janssen COVID-19 vaccine until further notice. Click here for the full statement.Reference: Page K, Melia M, Veenhuis R, et al. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med 2021; 384:541-549. DOI: 10.1056/NEJMoa2023345Fact Sheet for Healthcare Providers Administering Vaccine Emergency Use Authorization of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019. https://www.fda.gov/media/146304/download CPE details for GameChangers Podcast April 2021Learning Objective: Describe the outcomes of a recently published trial on hepatitis C vaccine candidates.0107-0000-21-158-H01-P0.2 CEU/2 Hrs (Knowledge)Initial Release Date: 04/06/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Aspirgillosis is a deadly fungal infection that is a major cause of mortality in patients with impaired immune systems. The current standard of care has been voriconazole due to the favorable side effect profile compared to amphotericin. However, posaconazole may not have there adverse effects and be a reasonable course of therapy. Is voriconazole just just a phase?Today's episode is sponsored by a special CEimpact FREE Law focused webinar: Save your spot - FREE LIVE LAW CEwebinar on April 1st.  SPOTS ARE LIMITED!https://ceimpact.com/law Reference: Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140- 6736(21)00219-1. PMID: 33549194.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 63, Issue 4, 15 August 2016, Pages e1–e60, hMps://doi.org/10.1093/cid/ciw326CPE details for GameChangers Podcast March 2021Learning Objective: Develop appropriate treatment of aspergillosis infections based on clinical studies.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcastSee omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The recently published STEP trial showed a dramatic effect on weight loss with the weekly injectable semaglutide versus placebo. Lay media picked up the headlines from this potential "GameChanger" medication for weight loss. With this one shot will patient lose themselves?Reference: Wilding J, Batterham R, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. February 10, 2021. DOI: 10.1056/NEJMoa2032183CPE details for GameChangers Podcast March 2021Learning Objective: Discuss the design of the STEP trial0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The endocannabinoid system is influenced by compounds found the Cannabis genus of plants and involves two compounds: cannabidiol (CBD) and tetrahydrocannabinol (THC). Federal and state regulation is changing, so the medicinal and recreatoinal use of cannabis-related prodcuts continues to increase. Although not life-threatening, some patients may experience Cannabis Hyperemesis Syndrome. Fortunately, a narrative review outlines the causes and treatment to help get out the weeds of treatment.Reference: Perisetti A, Gajendran M, Dasari C, et al. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Annals of Gastroenterology (2020) 33, 1-8. http://www.annalsgastro.gr/files/journals/1/earlyview/2020/ev-09-2020-01-AG_5230-0528.pdf CPE details for GameChangers Podcast March 2021Learning Objective: Describe the potential mechanisms and treatment options for Cannabis Hyperemesis Syndrome.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The recently published (in a pre-print server) COLCORONA study, sponsored by the Montreal Heart institute and conducted in 6 countries aimed to show if using colchicine would decrease risk of hospitalization and death in outpatients with COVID-19. Will it work? How's the study design? Learn the facts.Reference: Tardif J, Bouabdallaoui N, L'Allier P, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Pre-Print. https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1CPE details for GameChangers Podcast March 2021Learning Objective: Apply the results of the CORCORONA study to patients with COVID-19 disease.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The United States Preventative Services Task Force (USPSTF) recommendations for tobacco cessation have been recently updated. While no major changes to pharmacotherapy recommendations are in the new guidelines, the paper does emphasize that all health care providers can work with patients to help them achieve tobacco freedom. Learn how to support patients in your community.Reference: USPSTF Recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions CPE details for GameChangers Podcast February 2021Learning Objective: Discuss the rates of tobacco cessation and adverse effects of current Food and Drug Administration approved therapy for tobacco cessation.0107-0000-21-083-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The National Asthma Education and Prevention Program released the 2020 Asthma Guideline Update in December 2020. This guideline, published in JAMA, is different from the internal Global Initative for Asthma (GINA) guidelines and represents the first update since 2007. Learn about what makes these guidelines unique and how healthcare providers can maintain breaths.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Commentary: Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. JAMA. 2020;324(22):2301–2317. doi:10.1001/jama.2020.21974 Guidelines: 2020 Focused Updates to the Asthma Management Guidelines. https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines CPE details for GameChangers Podcast February 2021Learning Objective: Describe recommended therapy based on the staging on asthma in individuals 12 years or olderGuest Faculty: Kelli Cunningham, PharmD, BCPSDr. Cunningham reports no actual or potential conflicts of interest in relation to this episode of GameChangers.0107-0000-21-083-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon!This episode is accredited for CPE. Subscribe at CEimpact( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed athttps://www.idsociety.org/practice-guideline/lyme-disease/ CPE details for GameChangers Podcast February 2021Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms0107-0000-21-XXX-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

In December 2020, the American College of Cardiology published an Expert Consensus Decision Pathway for Antithrombotic Therapy in Patients undergoing Percutaneous Coronary Intervention. This guideline addresses a timely problem of patients on anticoagulation and antiplatelet therapy.This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Dec 18, 2020. Epublished DOI: 10.1016/j.jacc.2020.09.011. Accessed at https://www.jacc.org/doi/10.1016/j.jacc.2020.09.011CPE details for GameChangers Podcast January 2021Learning Objective: Recommend an appropriate antithrombotic/anticoagulant regimen in a patient who has received percutaneous coronary intervention with stenting0107-0000-21-079-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 01/25/21Expiration Date: 01/26/24Additional CPE information is located at https://www.ceimpact.com/podcastSee omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The unbelievable happened in 2020 - a vaccine was developed with high efficacy within 12 months for a novel virus! In December two vaccines for the prevention of the SARS-CoV-2 virus were approved through Emergency Use Authorization in the US. Is it time to get a shot?This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Polack F, Thomas S, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. NEJM. Dec 10, 2020. DOI: 10.1056/NEJM2034577Baden L, El Sahly H, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. Dec 30, 2020. DOI: 10.1056/NEHMoa2035389ACIP Recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Every December, the American Diabetes Association updates the Standards of Medical Care in Diabetes. The guidelines cover sixteen sections from diabetes advocacy to technology updates. Start 2021 off right - learn what changed and what matters most for individuals with diabetes.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: American Diabetes Association. Standards of Medical Care in Diabetes - 2021. Diabetes Cares. January 01, 2021; volume 44, issue supplement 1. https://care.diabetesjournals.org/content/44/Supplement_1 Disclosure: Dr. Jake Galdo is a speaker for Novo Nordisk in 2021.See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Myopathy is a common reason for discontinuation of statin medications. The recent SAMSON study examined the nocebo effect and how this may bias patients towards treatment failure. How can clinicians overcome the nocebo effect?This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Wood F, Howard J, Finegold J, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med 2020; 383:2182-2184. DOI: 10.1056/NEJMc2031173See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The efficacy of antiretroviral therapy has led to persons with HIV living a near-normal lifespan. But medications only work when used appropriately. The International Antiviral Society-USA Panel published updated recommendations for the treatment and prevention of HIV infections. Treatment of HIV may be distilled into a simple idea - two "nucs" and something else. Learn how to optimize care for your patients.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651-1669. Available at: https://www.iasusa.org/2020/11/12/antiretroviral-drugs-treatment-prevention-hiv-infection-adults-2020-recommendations-of-the-international-antiviral-society-usa-panel/ The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Clostridioides difficile is an important cause of morbidity and mortality in the United States with over 500,000 infections annually. The Infectious Disease Society of America released a clinical quality measure focused on treatment of c diff in March 2020. A review of the diagnosis and treatment will help providers improve quality.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The question of acetaminophen versus ibuprofen may finally be laid to rest. A recent meta-analysis compared the efficacy and safety of ibuprofen versus acetaminophen for the treatment of fever or pain in children younger than 2 years. Is there a drug of choice?Reference: Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(10):e2022398. doi:10.1001/jamanetworkopen.2020.22398This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Atopic Dermatitis is not extensively taught in pharmacy curriculum. With several international medical societies publishing updated guidelines and newly approved medications, it's time for a review. Clinicians can learn ways to help treat patients under the skin.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The opioid epidemic is helping reduce prescriptions for opioid-based pharmacotherapy. However, parallel to this drop has been an increase in gabapentin and pregabalin prescriptions.  Why has this occurred and what should the clinician know about this phenomenon?Additional Resources/References: Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016. Zhou L, Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, Wilson DL, Brown JD, Lo-Ciganic WH. J Clin Med. 2019 Dec 29;9(1):83. doi:10.3390/jcm9010083.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Sodium Glucose Co-Transporter-2 Inhibitors, a medication class for the treatment of diabetes, is now showing benefits in other medical conditions, like heart failure and kidney disease. Is this a class effect?Additional Resources/References: McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis . JAMA Cardiol. Published online October 07, 2020. doi:10.1001/jamacardio.2020.4511This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today! See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Vancomycin, despite being around for decades, keeps having updates to dosing, formulations, and monitoring. It's important to stay updated on this vital medication for hospital and infusion center practitioners. Are you ready for the changes?Additional Resources/References: https://www.idsociety.org/practice-guideline/vancomycin/This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections.  See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram